The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The efficacy & toxicity of venetoclax-based combination therapies in CLL
Lukas Smolej, MD, PhD, Charles University, Hradec Králové, Czech Republic, comments on the possibility of combining venetoclax with BTK inhibitors or monoclonal antibodies in chronic lymphocytic leukemia (CLL), discussing the efficacy and toxicity of these treatment regimens and their place in the frontline and relapsed/refractory (R/R) setting. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
